← Leaderboards
Kevin Loring Winthrop
Oregon Health & Science University
$7,724,085
Attributed
$14,276,797
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,035,748 · 5
FDA$1,796,668 · 1
AHRQ$444,381 · 1
By mechanism
R01$6,615,359 · 3
U01$3,863,432 · 1
UM1$3,112,747 · 1
K08$444,381 · 1
R34$240,878 · 1
Top collaborators
- Jeffrey R. Curtis5 shared
- Edwin W Rubel4 shared
- David M. Lewinsohn2 shared
- Shannon K Mcweeney2 shared
- Susan E Dorman1 shared
- Tony Y. Hu1 shared
- Bo Ning1 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Emily M. Henkle$2,455,143
- Cara Varley$679,546
- Gabrielle Helena Saunders$1,213,658
- Xammy Huu Wrynla$54,538
Others in their field
Top investigators on “Chronic”
- Judith S. Currier · University Of California Los Angeles$245,012,139
- Lawrence Corey · Fred Hutchinson Cancer Center$209,947,290
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$201,828,077
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$173,476,538
- John M Lachin · George Washington University$125,152,883
- David M Nathan · Massachusetts Institute Of Technology$120,438,756
Research focus
ChronicResponseElderlyRandomizedNon-Tuberculosis MycobacteriaAntibioticsSafetyPublishingPharmaceutical PreparationsInfectionDiagnosisSerious Adverse EventSymptomsDouble-Blind MethodAffectPreventionPharmacotherapyExposure ToBiological Response Modifier TherapyEvaluationQuality Of LifeHearing ImpairmentCommunicable DiseasesLife
Grant awards (22)
Mycobacterium avium complex pulmonary infection: immunologic and transcriptomic signatures of disease and treatment response$2,335,860
R01 · FY2025 · AI · contact PI
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection$1,093,054
U01 · FY2025 · DC · contact PI
CRISPR detection of circulating cell-free Mycobacterium avium complex (MAC) DNA for rapid diagnosis and monitoring of MAC pulmonary disease$742,807
R01 · FY2025 · AI · contact PI
Novel strategies for treatment of Mycobacterium abscessus pulmonary disease$240,878
R34 · FY2025 · AI
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection$1,067,890
U01 · FY2024 · DC · contact PI
Mycobacterium avium complex pulmonary infection: immunologic and transcriptomic signatures of disease and treatment response$873,166
R01 · FY2024 · AI · contact PI
CRISPR detection of circulating cell-free Mycobacterium avium complex (MAC) DNA for rapid diagnosis and monitoring of MAC pulmonary disease$866,858
R01 · FY2024 · AI · contact PI
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection$1,044,582
U01 · FY2023 · DC · contact PI
P2 Study of Clofazimine for Pulmonary M. avium Disease IND 125,266 (1/5/2015)$185,000
R01 · FY2023 · FD · contact PI
Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Ototoxicity in Patients Receiving Intravenous Amikacin for Treatment of Non-Tuberculous Mycobacterium Infection$657,906
U01 · FY2022 · DC · contact PI
P2 Study of Clofazimine for Pulmonary M. avium Disease IND 125,266 (1/5/2015)$133,054
R01 · FY2022 · FD · contact PI
P2 Study of Clofazimine for Pulmonary M. avium Disease IND 125,266 (1/5/2015)$492,780
R01 · FY2020 · FD · contact PI
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)$654,455
UM1 · FY2019 · AR
P2 Study of Clofazimine for Pulmonary M. avium Disease IND 125,266 (1/5/2015)$495,835
R01 · FY2019 · FD · contact PI
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)$614,070
UM1 · FY2018 · AR
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)$612,746
UM1 · FY2016 · AR
P2 Study of Clofazimine for Pulmonary M. avium Disease IND 125,266 (1/5/2015)$489,999
R01 · FY2016 · FD · contact PI
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)$606,509
UM1 · FY2015 · AR
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)$624,967
UM1 · FY2014 · AR
Mycobacterial disease prevention: pharmacovigilance and inflammatory disease$148,127
K08 · FY2010 · HS · contact PI
Mycobacterial disease prevention: pharmacovigilance and inflammatory disease$148,127
K08 · FY2009 · HS · contact PI
Mycobacterial disease prevention: pharmacovigilance and inflammatory disease$148,127
K08 · FY2008 · HS · contact PI